DNA Vaccination Elicits Immune Response in Prostate Cancer Patients

Strategic Insights -

Scientists in Sweden conducted a phase I trial to evaluate the safety, feasibility, and biological efficacy of a DNA vaccine expressing prostate-specific antigen (PSA) in patients with hormone-refractory prostate cancer. The study's objective was to assess whether DNA vaccination could induce an immune response against PSA in patients with prostate cancer. The results showed that DNA vaccination with a plasmid expressing PSA, combined with cytokines granulocyte/macrophage-colony stimulating factor (GM-CSF) and interleukin-2 (IL-2), was safe and induced a cellular and humoral immune response against PSA in two out of three patients in the highest dose cohort.

Key Takeaways:

  • The study involved eight patients with hormone-refractory prostate cancer who received the DNA vaccine in three different dose cohorts: 100, 300, and 900 micrograms.
  • Two out of three patients in the highest dose cohort (900 micrograms) exhibited a PSA-specific cellular immune response, measured by interferon-gamma (IFN-gamma) production against recombinant PSA protein.
  • A rise in anti-PSA immunoglobulin G (IgG) was detected in the same two patients in the highest dose cohort.
  • No adverse effects were observed in any of the dose cohorts.
  • The study demonstrated that DNA vaccination with a PSA-coding plasmid vector, combined with GM-CSF and IL-2, is safe and can induce a cellular and humoral immune response against PSA protein.

Statistics:

  • Eight patients with hormone-refractory prostate cancer participated in the study.
  • Three patients each received the vaccine in the 100, 300, and 900 microgram dose cohorts.
  • Two out of three patients in the highest dose cohort exhibited a PSA-specific cellular immune response.
  • No adverse effects (WHO grade 4 except 2) were observed in any dose cohort.
  • The study highlighted the potential of DNA vaccination as a novel immunotherapeutic approach for prostate cancer.

Sources:

  • Pavlenko, M., et al. (2004). A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Brit J Cancer, 91(4), 688-694.